<DOC>
	<DOCNO>NCT02060409</DOCNO>
	<brief_summary>In era hypomethylating agent MDS treatment , investigator aim investigate prognostic impact mutation spliceosome machinery gene ( SRSF2 , U2AF1 , ZRSR2 ) outcomes 1st line decitabine treatment MDS .</brief_summary>
	<brief_title>Prognostic Molecular Markers Patients With Myelodysplastic Syndrome</brief_title>
	<detailed_description>A number study try investigate clinical impact mutation spliceosomal machinery gene MDS fail demonstrate consistent prognostic relevance . Moreover , clinical impact mutation outcomes hypomethylating agent treatment MDS never explore yet . The investigator investigate prognostic impact mutation spliceosome machinery gene ( SRSF2 , U2AF1 , ZRSR2 ) outcomes 1st line decitabine treatment MDS .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<criteria>de novo MDS patient include study receive 1st line decitabine treatment adequate genomic DNA pretreated bone marrow sample therapyrelated MDS</criteria>
	<gender>All</gender>
	<minimum_age>17 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>myelodysplastic syndrome</keyword>
	<keyword>decitabine</keyword>
	<keyword>spliceosome mutation</keyword>
</DOC>